ID
21144
Description
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00440388
Link
https://clinicaltrials.gov/show/NCT00440388
Keywords
Versions (1)
- 4/11/17 4/11/17 -
Uploaded on
April 11, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Follicular Lymphoma NCT00440388
Eligibility Follicular Lymphoma NCT00440388
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Lymphoma-related symptoms
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0024299
- UMLS CUI [1,2]
- C1457887
Description
Active infection
Data type
boolean
Alias
- UMLS CUI [1]
- C0009450
Description
History of hepatitis b infection
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0019163
- UMLS CUI [1,2]
- C0262926
Description
Other lymphoma
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0024299
- UMLS CUI [1,2]
- C0205394
Description
CNS Lymphoma
Data type
boolean
Alias
- UMLS CUI [1]
- C0280803
Similar models
Eligibility Follicular Lymphoma NCT00440388
- StudyEvent: Eligibility
C0518015 (UMLS CUI [2])
C0232804 (UMLS CUI [2])
C0201899 (UMLS CUI [2])
C1457887 (UMLS CUI [1,2])
C0262926 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])